Jon Curwen

4.4k total citations · 1 hit paper
31 papers, 2.7k citations indexed

About

Jon Curwen is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Jon Curwen has authored 31 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Organic Chemistry. Recurrent topics in Jon Curwen's work include PI3K/AKT/mTOR signaling in cancer (9 papers), Protein Kinase Regulation and GTPase Signaling (8 papers) and Angiogenesis and VEGF in Cancer (7 papers). Jon Curwen is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (9 papers), Protein Kinase Regulation and GTPase Signaling (8 papers) and Angiogenesis and VEGF in Cancer (7 papers). Jon Curwen collaborates with scholars based in United Kingdom, United States and France. Jon Curwen's co-authors include Laurent Hennequin, Stephen R. Wedge, Jane Kendrew, Elaine S. E. Stokes, Donald Ogilvie, Patrick A. Plé, Andrew P. Thomas, Michael Dukes, Christine Lambert‐van der Brempt and Helen Musgrove and has published in prestigious journals such as PLoS ONE, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Jon Curwen

31 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

2002 702 citations Stephen R. Wedge, Donald Ogilvie et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jon Curwen United Kingdom	20	1.5k	1.0k	634	491	406	31	2.7k
Laurent Hennequin France	22	1.5k 1.0×	973 1.0×	500 0.8×	773 1.6×	341 0.8×	52	2.7k
Jane Kendrew United Kingdom	22	1.5k 1.0×	1.1k 1.1×	638 1.0×	295 0.6×	561 1.4×	33	2.7k
Gerhard Siemeister Germany	32	2.2k 1.5×	959 1.0×	411 0.6×	430 0.9×	594 1.5×	68	3.3k
Randall Schreck United States	9	1.5k 1.0×	686 0.7×	318 0.5×	226 0.5×	469 1.2×	13	2.3k
Richard Kendall United States	24	1.8k 1.2×	837 0.8×	268 0.4×	315 0.6×	476 1.2×	43	3.0k
Gordon Alton United States	18	1.8k 1.2×	739 0.7×	646 1.0×	390 0.8×	221 0.5×	42	2.8k
David Lebwohl United States	18	1.8k 1.2×	1.1k 1.1×	390 0.6×	236 0.5×	360 0.9×	31	3.2k
Peter F. Lebowitz United States	24	2.3k 1.6×	1.8k 1.8×	411 0.6×	167 0.3×	422 1.0×	40	3.2k
Mathias Schmidt Germany	25	1.3k 0.8×	1.1k 1.0×	274 0.4×	145 0.3×	278 0.7×	59	2.2k
Lanxi Song United States	20	2.2k 1.5×	2.1k 2.1×	701 1.1×	192 0.4×	664 1.6×	23	3.9k

Countries citing papers authored by Jon Curwen

Since Specialization

Citations

This map shows the geographic impact of Jon Curwen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Curwen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Curwen more than expected).

Fields of papers citing papers by Jon Curwen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Curwen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Curwen. The network helps show where Jon Curwen may publish in the future.

Co-authorship network of co-authors of Jon Curwen

This figure shows the co-authorship network connecting the top 25 collaborators of Jon Curwen. A scholar is included among the top collaborators of Jon Curwen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jon Curwen. Jon Curwen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Michaloglou, Chrysiis, Claire Crafter, Rasmus Siersbæk, et al.. (2018). Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer. Molecular Cancer Therapeutics. 17(5). 908–920. 128 indexed citations

Degorce, Sébastien L., Scott Boyd, Jon Curwen, et al.. (2016). Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R). Journal of Medicinal Chemistry. 59(10). 4859–4866. 23 indexed citations

Guichard, Sylvie M., Jon Curwen, Teeru Bihani, et al.. (2015). AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules. Molecular Cancer Therapeutics. 14(11). 2508–2518. 103 indexed citations

Vincent, Emma E., Douglas J.E. Elder, Jon Curwen, et al.. (2013). Targeting Non-Small Cell Lung Cancer Cells by Dual Inhibition of the Insulin Receptor and the Insulin-Like Growth Factor-1 Receptor. PLoS ONE. 8(6). e66963–e66963. 30 indexed citations

Ducray, Richard, Clifford D. Jones, Frédéric Jung, et al.. (2011). Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: Optimization of the aniline. Bioorganic & Medicinal Chemistry Letters. 21(16). 4702–4704. 36 indexed citations

Bagnato, Anna, Marilena Loizidou, B R Pflug, Jon Curwen, & J Growcott. (2011). Role of the endothelin axis and its antagonists in the treatment of cancer. British Journal of Pharmacology. 163(2). 220–233. 92 indexed citations

Green, Tim P., Jon Curwen, Vivien N. Jacobs, et al.. (2009). Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular Oncology. 3(3). 248–261. 176 indexed citations

Luke, Richard, Peter Ballard, David Buttar, et al.. (2009). Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo. Bioorganic & Medicinal Chemistry Letters. 19(23). 6670–6674. 31 indexed citations

Curwen, Jon & Stephen R. Wedge. (2009). The Use and Refinement of Rodent Models in Anti-cancer Drug Discovery: A Review. Alternatives to Laboratory Animals. 37(2). 173–180. 4 indexed citations

10.

Curwen, Jon, Helen Musgrove, Jane Kendrew, et al.. (2008). Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy. Clinical Cancer Research. 14(10). 3124–3131. 70 indexed citations

11.

Williams, Elizabeth D., et al.. (2007). The combination of the specific endothelin A receptor antagonist ZD4054 and submaximal bisphosphonate pamidronate prevents soft-tissue metastasis. QUT ePrints (Queensland University of Technology). 1 indexed citations

12.

Pflug, Beth R., et al.. (2007). Defining the basis of an operational model for enhanced efficacy of combination therapy using an endothelin receptor antagonist and chemotherapeutic agents. Molecular Cancer Therapeutics. 6. 5 indexed citations

13.

Curwen, Jon, Gareth Hughes, Nigel Curtis, et al.. (2007). The impact of ZD4054, a specific endothelin A receptor antagonist, on tumor blood supply, invasion, and the bone microenvironment. Molecular Cancer Therapeutics. 6. 2 indexed citations

14.

Growcott, J, et al.. (2007). Phenotypic in vitro differentiation of the specific endothelin A receptor antagonist, ZD4054, from the selective endothelin antagonist, atrasentan. Molecular Cancer Therapeutics. 6. 1 indexed citations

15.

Westwood, F. Russell, et al.. (2007). Effect of Pretreatment With Atenolol and Nifedipine on ZD6126-Induced Cardiac Toxicity in Rats. JNCI Journal of the National Cancer Institute. 99(22). 1724–1728. 22 indexed citations

16.

Hennequin, Laurent, J M Allen, J. Breed, et al.. (2006). N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor. Journal of Medicinal Chemistry. 49(22). 6465–6488. 283 indexed citations

17.

Morris, Clive, et al.. (2005). Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. British Journal of Cancer. 92(12). 2148–2152. 67 indexed citations

18.

Wedge, Stephen R., Jane Kendrew, Jon Curwen, et al.. (2004). The VEGF receptor tyrosine kinase inhibitor AZD2171 inhibits VEGF signaling, angiogenesis, and tumor growth in vivo. Cancer Research. 64. 1052–1052. 7 indexed citations

19.

Plé, Patrick A., Tim P. Green, Laurent Hennequin, et al.. (2004). Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src. Journal of Medicinal Chemistry. 47(4). 871–887. 139 indexed citations

20.

Hennequin, Laurent, Elaine S. E. Stokes, Andrew P. Thomas, et al.. (2002). Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry. 45(6). 1300–1312. 254 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact